SlideShare a Scribd company logo
Getting the most out of EHA
as a patient advocate
EHA and EuroBloodNET
Patient Advocacy Capacity Building Meeting
officially endorsed by EHA!
22 June 2017
Jan Geissler
Leukemia Patient Advocates Foundation, EHA European Affairs Committee,
EuroBloodNet ePAG
jan@cmladvocates.net, @jangeissler
Official objectives of the EHA congress
(for hematologists)
• Enhance knowledge of evidence-based approaches on
diagnosis and treatment for hematologic diseases.
• Access the latest research results (clinical, translational)
• Be updated on emerging innovative techniques,
diagnostic tools and risk-assessment strategies in
hematology and its subspecialties.
• Communicate, collaborate and network with
representatives of a large international audience –
medical professionals, national hematology societies,
patient groups, medical industry and the media.
Why are we patient advocates here?
• Understand science!
• Inform your members and patients about newest findings, good and
bad research
• Bring the patient voice into research, by speaking e.g. to clinicians
and industry
• Address relevant topics to hematologists and industry!
• Patient Advocacy Track sessions
• EHA Advocacy Track
• Education Sessions
• Scientific sessions
• Meet up - everyone is here!
• Everyone is here at the largest European hematology congress with
10 000+ participants: clinicians, researchers, nurses, diagnostics
experts, industry, medical societies,
Setting your priorities at EHA
• Think about impact for your community, not presence or
representation.
• You could spend all your days at EHA meeting with pharma
representatives, societies and other advocates, but is this why
you came to EHA in Madrid? What is the outcome?
• EHA is the best place to learn about newest science and
clinical progress – not only from the „Key Opinion Leaders“,
but from the second row of key people behind the scenes
• Prioritize the EHA sessions,
build your schedule around this,
refuse to attend other meetings during those sessions!
Too
complex?
Just for
clinicians?
NO!
Plenary sessions
• Usually opening ceremony, research
awards, cross-cutting topics, or other
key topics that are seen by
hematologists of key importance
• Patient advocates are usually less
interested across diseases, so „cherry-
picking“ of specific presentation might
be best strategy
Satellite symposia
• Symposia sponsored by a single company
on a specific topic/disease
• Run on Thursday (today), the day before the
scientific meeting
• Often in parallel to other meetings, e.g.
investigator meetings, or our meeting here
• Data presented here is
• usually „pharma-compliant“
• usually less complex, more mainstream,
more educational, good for the „big
picture“
• already published – data presented for the
first time at EHA will only be shown in the
scientific sessions
• This year in parallel to our capacity building
meeting
Education Sessions
• Overview on the „state of play“ and the
most important news in your disease area
• Usually less complex,
good to get the „big picture“
• Usually repeated twice on two different
days, to allow to participate in two,
and to overcome overlaps
• Don‘t miss „your“ education session,
they are the basis for the scientific
sessions at the congress!
Simultaneous/oral sessions
• Submitted in March. 195 of them selected in
April by EHA Scientific Programme Committee
• Those who make it into the „oral sessions“ were
rated highest – this is usually the „hot stuff“
• Clinical sessions are very relevant but complex.
Forget about biology sessions – hardcore
science!
• Each session has 75 minutes, with 5
presentations of 15 minutes including Q&A from
the audience
• To prepare yourself,
• Read the abstract of the session (on the web) prior
to the session
• Make yourself familiar with typical abbreviations
• Make yourself heard - queue up to ask a question!
Advocacy Sessions
• Core target group: Hematologists!
• 2 „Patient Advocacy sessions“ defined by
patient advocates
• Innovative Clinical Trial Designs, Adaptive
Pathways (MAPPs) and Patient Involvement in
R&D (Saturday, 8:00-9:30, N115)
• Pregnancy During and After Treatment: Myths
and Reality (Saturday, 11:30-12:45, N115)
• 2 “Advocacy Sessions” defined by EHA
• EU Funded Projects in Hematology: HARMONY
(Saturday, 14:45-15:45, N115)
• New drugs in hematology: Fair pricing & access
(Saturday, 16:00-17:15)
Engage in the EHA Patient Organisations
Workgroup to propose topics for 2018!
Poster sessions
• This is the best place to meet key experts and their
key staff members!
• „Hot topics“ for us are often on the 500 posters
(e.g. QoL, side effects, economics)
• Go, ask, understand - there are no silly questions!
How do I find interesting posters?
• Go to the meeting planner,
find your disease area
• Ignore „Biology“ (hardcore
science) – look for „Clinical“
• „First author“ needs to
stand in front of his/her
poster for 1,5 hours –
perfect opportunity, he/she
can‘t escape!
• Note down the lowest and
highest poster number of
interest
• Go to Poster area (Hall 7)
and find the poster area,
they are sorted by poster
number.
• Note: There are different
posters on different days!
X
X
X
Why are abstracts so important?
• Abstracts are short summaries of scientific news submitted
by clinicians who apply to present them at EHA
• They are available before the congress starts
 read and prepare
• After the congres, they can help you getting the facts right
in your EHA report
How do I access the abstracts?
• Go to EHA congress website, „Abstracts Online“
• Select 22nd EHA congress, then e.g. oral or posters
• Enter your disease area. Identify those abstracts whose headline is
most relevant. Then read the relevant abstracts
Patient Advocacy Booth:
our meeting point
• Joint booth of the EHA Patient Organisations Workgroup
(European umbrella organisations)
• Use this as your meeting point.
You can still go for a coffee at a nearby expo booth
• Booth number #560 this year
How do I find people from companies in
my region or Europe at EHA?
• Usually the patient relations people of all companies are
at EHA.
• They usually check their email and WhatsApp during the
congress.
• Ask other advocates if they have the contact.
• You can also ask staff at the booth of the company.
How do I find a clinician who is at EHA?
• Check the EHA abstracts in the EHA App or web-based
programme. If they are mentioned as first author of an
abstract:
• In case of a poster abstract, see them at the poster
session
• In case of an oral presentation, speak to them after
their talk
• Clinicians usually go to the scientific sessions presented
by colleagues. You might find him/her there
• Send them an email and ask for a meeting during EHA.
For future years: Their schedule is usually very full, so try
to ask them for an appointment several weeks in
advance.
How do I meet and connect with other
patient advocates?
• Go to the Patient Advocacy Booth
• Attend all Patient Advocacy Track sessions
• Join our EHA Advocates Facebook Group
at http://fb.me/ehaadvocates
• Join our Tapas meeting at 21:00 tonight
El Patio de la Casa de Córdoba, C/ Víctor de la Serna, 30 Madrid, 28016
• Volunteer to help organise future Patient Advocacy
Tracks and Capacity Building sessions
Providing feedback to your community:
Writing reports
• Take notes in scientific sessions
• Take photos of slides (secretly). Make sure you cover at least
the title slide and the conclusion slide(s), they are crucial.
• Look up its abstract later to support writing your report
• Take photos of posters. Have a barcode scanner on your
phone, often you can scan the poster and get a PDF by email.
• Download all interesting abstracts, simplify them and create
a summary for your patients.
• If you are writing a report on scientific matters, ask a friendly
clinician who is attending EHA to ensure accuracy.
• Think about who your audience is: Patients? Advocates?
Both? Member Organisations? Each of these may need a
differently written report
The bottom line:
How to get the most of EHA
• Think about your priorities
• There is no better place to meet clinicians and learn about
news that are crucial for the life of your patients
• Think about the impact for your community, not presence or
representation
• Build your schedule around the key congress sessions.
Refuse to attend other meetings during those sessions!
• Don’t go to meetings because you feel obliged, e.g. because
they have paid for your flight. You are here for the congress,
not to be somewhere else
• Learn, network, engage, explore:
And don’t forget: Be bold and have fun!
EHA / EuroBloodNet Capacity Building: Plenary
1. EuroBloodNet and the ePAG (Pierre Fenaux)
2. Getting the most out of EHA (Jan Geissler)
3. Interpreting and understanding scientific presentations (Tamás Bereczky)
Myeloma data at EHA 2017:
Anna Sureda
Acute Leukemias data at EHA 2017:
Gert Ossenkoppele
14:00
MPE Advocate
Development
Programme
MPN data at EHA 2017:
Clare Harrison
CML data at EHA 2017: Tim Brümmendorf
MDS data at EHA 2017: Pierre Fenaux
Lymphoma& CLL data at EHA2017:
Dr. John Gribben
15:15
15:25
16:55
Track 1, Room N117 Track 2, Room N118
Optional offsite capacity building meetings (optional)
17:30
21:00
Acute Leukemia
Advocates
Network
Joint tapas and drinks of advocates
El Patio de la Casa de Córdoba, C/ Víctor de la Serna, 30 Madrid, 28016
20:30
15:55
16:25
14:55
14:30
What‘s next?
Crowne Plaza Madrid
Airport Hotel

More Related Content

Similar to How to get the most of EHA as a patient advocate

European Patients’ Academy on Therapeutic Innovation: Shifting paradigms in ...
European Patients’ Academy on Therapeutic Innovation:Shifting paradigms in ...European Patients’ Academy on Therapeutic Innovation:Shifting paradigms in ...
European Patients’ Academy on Therapeutic Innovation: Shifting paradigms in ...
patvocates
 
Grindlay2008
Grindlay2008Grindlay2008
Jan Geissler - How Patient (Advocates) discuss Clinical Research on the Internet
Jan Geissler - How Patient (Advocates) discuss Clinical Research on the InternetJan Geissler - How Patient (Advocates) discuss Clinical Research on the Internet
Jan Geissler - How Patient (Advocates) discuss Clinical Research on the Internet
patvocates
 
Driving progress in healthcare through NHS research
Driving progress in healthcare through NHS researchDriving progress in healthcare through NHS research
Driving progress in healthcare through NHS research
Health and Care Innovation Expo
 
Addiction Therapy-2016
Addiction Therapy-2016Addiction Therapy-2016
Addiction Therapy-2016
Nick Johnson
 
PMI Masterclass - Derick Mitchell IPPOSI - October 19th 2016
PMI Masterclass - Derick Mitchell IPPOSI - October 19th 2016PMI Masterclass - Derick Mitchell IPPOSI - October 19th 2016
PMI Masterclass - Derick Mitchell IPPOSI - October 19th 2016
ipposi
 
CABs
CABsCABs
Data science sig june 23, 2017 introduction, comments and feedback
Data science sig june 23, 2017 introduction, comments and feedbackData science sig june 23, 2017 introduction, comments and feedback
Data science sig june 23, 2017 introduction, comments and feedback
Data Science NIH
 
NIH Data Science Special Interest Group
NIH Data Science Special Interest GroupNIH Data Science Special Interest Group
NIH Data Science Special Interest Group
Yaffa Rubinstien
 
Pediatriccardiology_2016_Brochure_New
Pediatriccardiology_2016_Brochure_NewPediatriccardiology_2016_Brochure_New
Pediatriccardiology_2016_Brochure_New
kiara Samantha
 
International Psoriasis Council, Steve O'Dell
International Psoriasis Council, Steve O'DellInternational Psoriasis Council, Steve O'Dell
Stratified Medicine Public Dialogue Case Study Part 3
Stratified Medicine Public Dialogue Case Study Part 3Stratified Medicine Public Dialogue Case Study Part 3
Stratified Medicine Public Dialogue Case Study Part 3
InvolveReema
 
Communicating for a Research Institution
Communicating for a Research InstitutionCommunicating for a Research Institution
Communicating for a Research Institution
Kara Gavin
 
Time For Extra Innings: Tossing Out A Few More Hospice & Palliative Care Elev...
Time For Extra Innings: Tossing Out A Few More Hospice & Palliative Care Elev...Time For Extra Innings: Tossing Out A Few More Hospice & Palliative Care Elev...
Time For Extra Innings: Tossing Out A Few More Hospice & Palliative Care Elev...
Stephen Leedy, MD MA FAAHPM HMDC
 
Good practices in patient involvement in HTA
Good practices in patient involvement in HTAGood practices in patient involvement in HTA
Good practices in patient involvement in HTA
EUPATI
 
Nephrology summit 2018 brochure
Nephrology summit 2018 brochureNephrology summit 2018 brochure
Nephrology summit 2018 brochure
Husna Gauhar
 
Ice to Eskimos: Making the Case for Hospice Care to a Death-Averse Society (N...
Ice to Eskimos: Making the Case for Hospice Care to a Death-Averse Society (N...Ice to Eskimos: Making the Case for Hospice Care to a Death-Averse Society (N...
Ice to Eskimos: Making the Case for Hospice Care to a Death-Averse Society (N...
Stephen Leedy, MD MA FAAHPM HMDC
 
Atelier utilisation des données probantes pour la CSU master presentation (1)...
Atelier utilisation des données probantes pour la CSU master presentation (1)...Atelier utilisation des données probantes pour la CSU master presentation (1)...
Atelier utilisation des données probantes pour la CSU master presentation (1)...
SelinaDefor
 
Let's Talk Research 2015 - Mel Chapman - Public involvement in the disseminat...
Let's Talk Research 2015 - Mel Chapman - Public involvement in the disseminat...Let's Talk Research 2015 - Mel Chapman - Public involvement in the disseminat...
Let's Talk Research 2015 - Mel Chapman - Public involvement in the disseminat...
NHSNWRD
 
Eurochioces at 20 AES Conference
Eurochioces at 20 AES ConferenceEurochioces at 20 AES Conference
Eurochioces at 20 AES Conference
Krijn Poppe
 

Similar to How to get the most of EHA as a patient advocate (20)

European Patients’ Academy on Therapeutic Innovation: Shifting paradigms in ...
European Patients’ Academy on Therapeutic Innovation:Shifting paradigms in ...European Patients’ Academy on Therapeutic Innovation:Shifting paradigms in ...
European Patients’ Academy on Therapeutic Innovation: Shifting paradigms in ...
 
Grindlay2008
Grindlay2008Grindlay2008
Grindlay2008
 
Jan Geissler - How Patient (Advocates) discuss Clinical Research on the Internet
Jan Geissler - How Patient (Advocates) discuss Clinical Research on the InternetJan Geissler - How Patient (Advocates) discuss Clinical Research on the Internet
Jan Geissler - How Patient (Advocates) discuss Clinical Research on the Internet
 
Driving progress in healthcare through NHS research
Driving progress in healthcare through NHS researchDriving progress in healthcare through NHS research
Driving progress in healthcare through NHS research
 
Addiction Therapy-2016
Addiction Therapy-2016Addiction Therapy-2016
Addiction Therapy-2016
 
PMI Masterclass - Derick Mitchell IPPOSI - October 19th 2016
PMI Masterclass - Derick Mitchell IPPOSI - October 19th 2016PMI Masterclass - Derick Mitchell IPPOSI - October 19th 2016
PMI Masterclass - Derick Mitchell IPPOSI - October 19th 2016
 
CABs
CABsCABs
CABs
 
Data science sig june 23, 2017 introduction, comments and feedback
Data science sig june 23, 2017 introduction, comments and feedbackData science sig june 23, 2017 introduction, comments and feedback
Data science sig june 23, 2017 introduction, comments and feedback
 
NIH Data Science Special Interest Group
NIH Data Science Special Interest GroupNIH Data Science Special Interest Group
NIH Data Science Special Interest Group
 
Pediatriccardiology_2016_Brochure_New
Pediatriccardiology_2016_Brochure_NewPediatriccardiology_2016_Brochure_New
Pediatriccardiology_2016_Brochure_New
 
International Psoriasis Council, Steve O'Dell
International Psoriasis Council, Steve O'DellInternational Psoriasis Council, Steve O'Dell
International Psoriasis Council, Steve O'Dell
 
Stratified Medicine Public Dialogue Case Study Part 3
Stratified Medicine Public Dialogue Case Study Part 3Stratified Medicine Public Dialogue Case Study Part 3
Stratified Medicine Public Dialogue Case Study Part 3
 
Communicating for a Research Institution
Communicating for a Research InstitutionCommunicating for a Research Institution
Communicating for a Research Institution
 
Time For Extra Innings: Tossing Out A Few More Hospice & Palliative Care Elev...
Time For Extra Innings: Tossing Out A Few More Hospice & Palliative Care Elev...Time For Extra Innings: Tossing Out A Few More Hospice & Palliative Care Elev...
Time For Extra Innings: Tossing Out A Few More Hospice & Palliative Care Elev...
 
Good practices in patient involvement in HTA
Good practices in patient involvement in HTAGood practices in patient involvement in HTA
Good practices in patient involvement in HTA
 
Nephrology summit 2018 brochure
Nephrology summit 2018 brochureNephrology summit 2018 brochure
Nephrology summit 2018 brochure
 
Ice to Eskimos: Making the Case for Hospice Care to a Death-Averse Society (N...
Ice to Eskimos: Making the Case for Hospice Care to a Death-Averse Society (N...Ice to Eskimos: Making the Case for Hospice Care to a Death-Averse Society (N...
Ice to Eskimos: Making the Case for Hospice Care to a Death-Averse Society (N...
 
Atelier utilisation des données probantes pour la CSU master presentation (1)...
Atelier utilisation des données probantes pour la CSU master presentation (1)...Atelier utilisation des données probantes pour la CSU master presentation (1)...
Atelier utilisation des données probantes pour la CSU master presentation (1)...
 
Let's Talk Research 2015 - Mel Chapman - Public involvement in the disseminat...
Let's Talk Research 2015 - Mel Chapman - Public involvement in the disseminat...Let's Talk Research 2015 - Mel Chapman - Public involvement in the disseminat...
Let's Talk Research 2015 - Mel Chapman - Public involvement in the disseminat...
 
Eurochioces at 20 AES Conference
Eurochioces at 20 AES ConferenceEurochioces at 20 AES Conference
Eurochioces at 20 AES Conference
 

More from jangeissler

Relevanz von Laienzusammenfassungen von Studienergebnissen für Patienten
Relevanz von Laienzusammenfassungen von Studienergebnissen für Patienten Relevanz von Laienzusammenfassungen von Studienergebnissen für Patienten
Relevanz von Laienzusammenfassungen von Studienergebnissen für Patienten
jangeissler
 
Don't just talk about patient centricity - put meaningful patient engagement ...
Don't just talk about patient centricity - put meaningful patient engagement ...Don't just talk about patient centricity - put meaningful patient engagement ...
Don't just talk about patient centricity - put meaningful patient engagement ...
jangeissler
 
CML: A tiger in the cage? A (European) perspective on CML disease management
CML: A tiger in the cage? A (European) perspective on CML disease managementCML: A tiger in the cage? A (European) perspective on CML disease management
CML: A tiger in the cage? A (European) perspective on CML disease management
jangeissler
 
Sicht der Patienten auf Real World Data, Register und Versorgungsdaten
Sicht der Patienten auf Real World Data, Register und VersorgungsdatenSicht der Patienten auf Real World Data, Register und Versorgungsdaten
Sicht der Patienten auf Real World Data, Register und Versorgungsdaten
jangeissler
 
Überblick der Aktivitäten von Leukämie-Online und CML Advocates Network
Überblick der Aktivitäten von Leukämie-Online und CML Advocates NetworkÜberblick der Aktivitäten von Leukämie-Online und CML Advocates Network
Überblick der Aktivitäten von Leukämie-Online und CML Advocates Network
jangeissler
 
Andreas Willer - Rehabilitation für Patienten mit CML
Andreas Willer - Rehabilitation für Patienten mit CMLAndreas Willer - Rehabilitation für Patienten mit CML
Andreas Willer - Rehabilitation für Patienten mit CML
jangeissler
 
Umfrage zur Therapiefreien Remission (TFR) der CML-Patientengemeinschaft
Umfrage zur Therapiefreien Remission (TFR) der CML-PatientengemeinschaftUmfrage zur Therapiefreien Remission (TFR) der CML-Patientengemeinschaft
Umfrage zur Therapiefreien Remission (TFR) der CML-Patientengemeinschaft
jangeissler
 
Patientenperspektive im Studiendesign
Patientenperspektive im Studiendesign Patientenperspektive im Studiendesign
Patientenperspektive im Studiendesign
jangeissler
 
Reasonable Legal Agreements between Patient Advocates and Pharma Companies
Reasonable Legal Agreements between Patient Advocates and Pharma CompaniesReasonable Legal Agreements between Patient Advocates and Pharma Companies
Reasonable Legal Agreements between Patient Advocates and Pharma Companies
jangeissler
 
Bericht LeukaNET / leukaemie-online.de und CML Advocates Network
Bericht LeukaNET / leukaemie-online.de und CML Advocates NetworkBericht LeukaNET / leukaemie-online.de und CML Advocates Network
Bericht LeukaNET / leukaemie-online.de und CML Advocates Network
jangeissler
 
European Patient Perspective on Access and Innovation with Multiplex Genomic ...
European Patient Perspective on Access and Innovation with Multiplex Genomic ...European Patient Perspective on Access and Innovation with Multiplex Genomic ...
European Patient Perspective on Access and Innovation with Multiplex Genomic ...
jangeissler
 
European Cancer Patient Advocacy: Introduction to the community, key stakehol...
European Cancer Patient Advocacy: Introduction to the community, key stakehol...European Cancer Patient Advocacy: Introduction to the community, key stakehol...
European Cancer Patient Advocacy: Introduction to the community, key stakehol...
jangeissler
 
Häufige Fragen von CML-Patienten und Welt-CML-Tag 2017
Häufige Fragen von CML-Patienten und Welt-CML-Tag 2017Häufige Fragen von CML-Patienten und Welt-CML-Tag 2017
Häufige Fragen von CML-Patienten und Welt-CML-Tag 2017
jangeissler
 
CML: What's New at EHA? Tim Brümmendorf, EHA Capacity Building Session, EHA c...
CML: What's New at EHA? Tim Brümmendorf, EHA Capacity Building Session, EHA c...CML: What's New at EHA? Tim Brümmendorf, EHA Capacity Building Session, EHA c...
CML: What's New at EHA? Tim Brümmendorf, EHA Capacity Building Session, EHA c...
jangeissler
 
PCR-Info-Projekt (Cornelia Borowczak)
PCR-Info-Projekt (Cornelia Borowczak)PCR-Info-Projekt (Cornelia Borowczak)
PCR-Info-Projekt (Cornelia Borowczak)
jangeissler
 
The Networked Patient Group: How technology changes the face of patient advocacy
The Networked Patient Group: How technology changes the face of patient advocacyThe Networked Patient Group: How technology changes the face of patient advocacy
The Networked Patient Group: How technology changes the face of patient advocacy
jangeissler
 
Tripartite dimension of interaction of patients, regulators and industry (Jan...
Tripartite dimension of interaction of patients, regulators and industry (Jan...Tripartite dimension of interaction of patients, regulators and industry (Jan...
Tripartite dimension of interaction of patients, regulators and industry (Jan...
jangeissler
 
Similarities and differences between Rare Cancers and Rare Diseases
Similarities and differences between Rare Cancers and Rare DiseasesSimilarities and differences between Rare Cancers and Rare Diseases
Similarities and differences between Rare Cancers and Rare Diseases
jangeissler
 
The role of patients and healthcare providers in translational medicine
The role of patients and healthcare providers in translational medicineThe role of patients and healthcare providers in translational medicine
The role of patients and healthcare providers in translational medicine
jangeissler
 
How to communicate scientific and medical information to patients, advocates ...
How to communicate scientific and medical information to patients, advocates ...How to communicate scientific and medical information to patients, advocates ...
How to communicate scientific and medical information to patients, advocates ...
jangeissler
 

More from jangeissler (20)

Relevanz von Laienzusammenfassungen von Studienergebnissen für Patienten
Relevanz von Laienzusammenfassungen von Studienergebnissen für Patienten Relevanz von Laienzusammenfassungen von Studienergebnissen für Patienten
Relevanz von Laienzusammenfassungen von Studienergebnissen für Patienten
 
Don't just talk about patient centricity - put meaningful patient engagement ...
Don't just talk about patient centricity - put meaningful patient engagement ...Don't just talk about patient centricity - put meaningful patient engagement ...
Don't just talk about patient centricity - put meaningful patient engagement ...
 
CML: A tiger in the cage? A (European) perspective on CML disease management
CML: A tiger in the cage? A (European) perspective on CML disease managementCML: A tiger in the cage? A (European) perspective on CML disease management
CML: A tiger in the cage? A (European) perspective on CML disease management
 
Sicht der Patienten auf Real World Data, Register und Versorgungsdaten
Sicht der Patienten auf Real World Data, Register und VersorgungsdatenSicht der Patienten auf Real World Data, Register und Versorgungsdaten
Sicht der Patienten auf Real World Data, Register und Versorgungsdaten
 
Überblick der Aktivitäten von Leukämie-Online und CML Advocates Network
Überblick der Aktivitäten von Leukämie-Online und CML Advocates NetworkÜberblick der Aktivitäten von Leukämie-Online und CML Advocates Network
Überblick der Aktivitäten von Leukämie-Online und CML Advocates Network
 
Andreas Willer - Rehabilitation für Patienten mit CML
Andreas Willer - Rehabilitation für Patienten mit CMLAndreas Willer - Rehabilitation für Patienten mit CML
Andreas Willer - Rehabilitation für Patienten mit CML
 
Umfrage zur Therapiefreien Remission (TFR) der CML-Patientengemeinschaft
Umfrage zur Therapiefreien Remission (TFR) der CML-PatientengemeinschaftUmfrage zur Therapiefreien Remission (TFR) der CML-Patientengemeinschaft
Umfrage zur Therapiefreien Remission (TFR) der CML-Patientengemeinschaft
 
Patientenperspektive im Studiendesign
Patientenperspektive im Studiendesign Patientenperspektive im Studiendesign
Patientenperspektive im Studiendesign
 
Reasonable Legal Agreements between Patient Advocates and Pharma Companies
Reasonable Legal Agreements between Patient Advocates and Pharma CompaniesReasonable Legal Agreements between Patient Advocates and Pharma Companies
Reasonable Legal Agreements between Patient Advocates and Pharma Companies
 
Bericht LeukaNET / leukaemie-online.de und CML Advocates Network
Bericht LeukaNET / leukaemie-online.de und CML Advocates NetworkBericht LeukaNET / leukaemie-online.de und CML Advocates Network
Bericht LeukaNET / leukaemie-online.de und CML Advocates Network
 
European Patient Perspective on Access and Innovation with Multiplex Genomic ...
European Patient Perspective on Access and Innovation with Multiplex Genomic ...European Patient Perspective on Access and Innovation with Multiplex Genomic ...
European Patient Perspective on Access and Innovation with Multiplex Genomic ...
 
European Cancer Patient Advocacy: Introduction to the community, key stakehol...
European Cancer Patient Advocacy: Introduction to the community, key stakehol...European Cancer Patient Advocacy: Introduction to the community, key stakehol...
European Cancer Patient Advocacy: Introduction to the community, key stakehol...
 
Häufige Fragen von CML-Patienten und Welt-CML-Tag 2017
Häufige Fragen von CML-Patienten und Welt-CML-Tag 2017Häufige Fragen von CML-Patienten und Welt-CML-Tag 2017
Häufige Fragen von CML-Patienten und Welt-CML-Tag 2017
 
CML: What's New at EHA? Tim Brümmendorf, EHA Capacity Building Session, EHA c...
CML: What's New at EHA? Tim Brümmendorf, EHA Capacity Building Session, EHA c...CML: What's New at EHA? Tim Brümmendorf, EHA Capacity Building Session, EHA c...
CML: What's New at EHA? Tim Brümmendorf, EHA Capacity Building Session, EHA c...
 
PCR-Info-Projekt (Cornelia Borowczak)
PCR-Info-Projekt (Cornelia Borowczak)PCR-Info-Projekt (Cornelia Borowczak)
PCR-Info-Projekt (Cornelia Borowczak)
 
The Networked Patient Group: How technology changes the face of patient advocacy
The Networked Patient Group: How technology changes the face of patient advocacyThe Networked Patient Group: How technology changes the face of patient advocacy
The Networked Patient Group: How technology changes the face of patient advocacy
 
Tripartite dimension of interaction of patients, regulators and industry (Jan...
Tripartite dimension of interaction of patients, regulators and industry (Jan...Tripartite dimension of interaction of patients, regulators and industry (Jan...
Tripartite dimension of interaction of patients, regulators and industry (Jan...
 
Similarities and differences between Rare Cancers and Rare Diseases
Similarities and differences between Rare Cancers and Rare DiseasesSimilarities and differences between Rare Cancers and Rare Diseases
Similarities and differences between Rare Cancers and Rare Diseases
 
The role of patients and healthcare providers in translational medicine
The role of patients and healthcare providers in translational medicineThe role of patients and healthcare providers in translational medicine
The role of patients and healthcare providers in translational medicine
 
How to communicate scientific and medical information to patients, advocates ...
How to communicate scientific and medical information to patients, advocates ...How to communicate scientific and medical information to patients, advocates ...
How to communicate scientific and medical information to patients, advocates ...
 

Recently uploaded

A Classical Text Review on Basavarajeeyam
A Classical Text Review on BasavarajeeyamA Classical Text Review on Basavarajeeyam
A Classical Text Review on Basavarajeeyam
Dr. Jyothirmai Paindla
 
Identification and nursing management of congenital malformations .pptx
Identification and nursing management of congenital malformations .pptxIdentification and nursing management of congenital malformations .pptx
Identification and nursing management of congenital malformations .pptx
MGM SCHOOL/COLLEGE OF NURSING
 
Management of Traumatic Splenic injury.pptx
Management of Traumatic Splenic injury.pptxManagement of Traumatic Splenic injury.pptx
Management of Traumatic Splenic injury.pptx
AkshaySarraf1
 
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdfCHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
rishi2789
 
Top-Vitamin-Supplement-Brands-in-India List
Top-Vitamin-Supplement-Brands-in-India ListTop-Vitamin-Supplement-Brands-in-India List
Top-Vitamin-Supplement-Brands-in-India List
SwisschemDerma
 
Top 10 Best Ayurvedic Kidney Stone Syrups in India
Top 10 Best Ayurvedic Kidney Stone Syrups in IndiaTop 10 Best Ayurvedic Kidney Stone Syrups in India
Top 10 Best Ayurvedic Kidney Stone Syrups in India
Swastik Ayurveda
 
Physiology of Chemical Sensation of smell.pdf
Physiology of Chemical Sensation of smell.pdfPhysiology of Chemical Sensation of smell.pdf
Physiology of Chemical Sensation of smell.pdf
MedicoseAcademics
 
Novas diretrizes da OMS para os cuidados perinatais de mais qualidade
Novas diretrizes da OMS para os cuidados perinatais de mais qualidadeNovas diretrizes da OMS para os cuidados perinatais de mais qualidade
Novas diretrizes da OMS para os cuidados perinatais de mais qualidade
Prof. Marcus Renato de Carvalho
 
How STIs Influence the Development of Pelvic Inflammatory Disease.pptx
How STIs Influence the Development of Pelvic Inflammatory Disease.pptxHow STIs Influence the Development of Pelvic Inflammatory Disease.pptx
How STIs Influence the Development of Pelvic Inflammatory Disease.pptx
FFragrant
 
CHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdfCHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdf
rishi2789
 
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
rishi2789
 
Adhd Medication Shortage Uk - trinexpharmacy.com
Adhd Medication Shortage Uk - trinexpharmacy.comAdhd Medication Shortage Uk - trinexpharmacy.com
Adhd Medication Shortage Uk - trinexpharmacy.com
reignlana06
 
Vestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptx
Vestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptxVestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptx
Vestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptx
Dr. Rabia Inam Gandapore
 
Cardiac Assessment for B.sc Nursing Student.pdf
Cardiac Assessment for B.sc Nursing Student.pdfCardiac Assessment for B.sc Nursing Student.pdf
Cardiac Assessment for B.sc Nursing Student.pdf
shivalingatalekar1
 
Knee anatomy and clinical tests 2024.pdf
Knee anatomy and clinical tests 2024.pdfKnee anatomy and clinical tests 2024.pdf
Knee anatomy and clinical tests 2024.pdf
vimalpl1234
 
Sex determination from mandible pelvis and skull
Sex determination from mandible pelvis and skullSex determination from mandible pelvis and skull
Sex determination from mandible pelvis and skull
ShashankRoodkee
 
Integrating Ayurveda into Parkinson’s Management: A Holistic Approach
Integrating Ayurveda into Parkinson’s Management: A Holistic ApproachIntegrating Ayurveda into Parkinson’s Management: A Holistic Approach
Integrating Ayurveda into Parkinson’s Management: A Holistic Approach
Ayurveda ForAll
 
The Electrocardiogram - Physiologic Principles
The Electrocardiogram - Physiologic PrinciplesThe Electrocardiogram - Physiologic Principles
The Electrocardiogram - Physiologic Principles
MedicoseAcademics
 
Physiology of Special Chemical Sensation of Taste
Physiology of Special Chemical Sensation of TastePhysiology of Special Chemical Sensation of Taste
Physiology of Special Chemical Sensation of Taste
MedicoseAcademics
 
Netter's Atlas of Human Anatomy 7.ed.pdf
Netter's Atlas of Human Anatomy 7.ed.pdfNetter's Atlas of Human Anatomy 7.ed.pdf
Netter's Atlas of Human Anatomy 7.ed.pdf
BrissaOrtiz3
 

Recently uploaded (20)

A Classical Text Review on Basavarajeeyam
A Classical Text Review on BasavarajeeyamA Classical Text Review on Basavarajeeyam
A Classical Text Review on Basavarajeeyam
 
Identification and nursing management of congenital malformations .pptx
Identification and nursing management of congenital malformations .pptxIdentification and nursing management of congenital malformations .pptx
Identification and nursing management of congenital malformations .pptx
 
Management of Traumatic Splenic injury.pptx
Management of Traumatic Splenic injury.pptxManagement of Traumatic Splenic injury.pptx
Management of Traumatic Splenic injury.pptx
 
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdfCHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
 
Top-Vitamin-Supplement-Brands-in-India List
Top-Vitamin-Supplement-Brands-in-India ListTop-Vitamin-Supplement-Brands-in-India List
Top-Vitamin-Supplement-Brands-in-India List
 
Top 10 Best Ayurvedic Kidney Stone Syrups in India
Top 10 Best Ayurvedic Kidney Stone Syrups in IndiaTop 10 Best Ayurvedic Kidney Stone Syrups in India
Top 10 Best Ayurvedic Kidney Stone Syrups in India
 
Physiology of Chemical Sensation of smell.pdf
Physiology of Chemical Sensation of smell.pdfPhysiology of Chemical Sensation of smell.pdf
Physiology of Chemical Sensation of smell.pdf
 
Novas diretrizes da OMS para os cuidados perinatais de mais qualidade
Novas diretrizes da OMS para os cuidados perinatais de mais qualidadeNovas diretrizes da OMS para os cuidados perinatais de mais qualidade
Novas diretrizes da OMS para os cuidados perinatais de mais qualidade
 
How STIs Influence the Development of Pelvic Inflammatory Disease.pptx
How STIs Influence the Development of Pelvic Inflammatory Disease.pptxHow STIs Influence the Development of Pelvic Inflammatory Disease.pptx
How STIs Influence the Development of Pelvic Inflammatory Disease.pptx
 
CHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdfCHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdf
 
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
 
Adhd Medication Shortage Uk - trinexpharmacy.com
Adhd Medication Shortage Uk - trinexpharmacy.comAdhd Medication Shortage Uk - trinexpharmacy.com
Adhd Medication Shortage Uk - trinexpharmacy.com
 
Vestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptx
Vestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptxVestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptx
Vestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptx
 
Cardiac Assessment for B.sc Nursing Student.pdf
Cardiac Assessment for B.sc Nursing Student.pdfCardiac Assessment for B.sc Nursing Student.pdf
Cardiac Assessment for B.sc Nursing Student.pdf
 
Knee anatomy and clinical tests 2024.pdf
Knee anatomy and clinical tests 2024.pdfKnee anatomy and clinical tests 2024.pdf
Knee anatomy and clinical tests 2024.pdf
 
Sex determination from mandible pelvis and skull
Sex determination from mandible pelvis and skullSex determination from mandible pelvis and skull
Sex determination from mandible pelvis and skull
 
Integrating Ayurveda into Parkinson’s Management: A Holistic Approach
Integrating Ayurveda into Parkinson’s Management: A Holistic ApproachIntegrating Ayurveda into Parkinson’s Management: A Holistic Approach
Integrating Ayurveda into Parkinson’s Management: A Holistic Approach
 
The Electrocardiogram - Physiologic Principles
The Electrocardiogram - Physiologic PrinciplesThe Electrocardiogram - Physiologic Principles
The Electrocardiogram - Physiologic Principles
 
Physiology of Special Chemical Sensation of Taste
Physiology of Special Chemical Sensation of TastePhysiology of Special Chemical Sensation of Taste
Physiology of Special Chemical Sensation of Taste
 
Netter's Atlas of Human Anatomy 7.ed.pdf
Netter's Atlas of Human Anatomy 7.ed.pdfNetter's Atlas of Human Anatomy 7.ed.pdf
Netter's Atlas of Human Anatomy 7.ed.pdf
 

How to get the most of EHA as a patient advocate

  • 1. Getting the most out of EHA as a patient advocate EHA and EuroBloodNET Patient Advocacy Capacity Building Meeting officially endorsed by EHA! 22 June 2017 Jan Geissler Leukemia Patient Advocates Foundation, EHA European Affairs Committee, EuroBloodNet ePAG jan@cmladvocates.net, @jangeissler
  • 2. Official objectives of the EHA congress (for hematologists) • Enhance knowledge of evidence-based approaches on diagnosis and treatment for hematologic diseases. • Access the latest research results (clinical, translational) • Be updated on emerging innovative techniques, diagnostic tools and risk-assessment strategies in hematology and its subspecialties. • Communicate, collaborate and network with representatives of a large international audience – medical professionals, national hematology societies, patient groups, medical industry and the media.
  • 3. Why are we patient advocates here? • Understand science! • Inform your members and patients about newest findings, good and bad research • Bring the patient voice into research, by speaking e.g. to clinicians and industry • Address relevant topics to hematologists and industry! • Patient Advocacy Track sessions • EHA Advocacy Track • Education Sessions • Scientific sessions • Meet up - everyone is here! • Everyone is here at the largest European hematology congress with 10 000+ participants: clinicians, researchers, nurses, diagnostics experts, industry, medical societies,
  • 4. Setting your priorities at EHA • Think about impact for your community, not presence or representation. • You could spend all your days at EHA meeting with pharma representatives, societies and other advocates, but is this why you came to EHA in Madrid? What is the outcome? • EHA is the best place to learn about newest science and clinical progress – not only from the „Key Opinion Leaders“, but from the second row of key people behind the scenes • Prioritize the EHA sessions, build your schedule around this, refuse to attend other meetings during those sessions!
  • 6.
  • 7. Plenary sessions • Usually opening ceremony, research awards, cross-cutting topics, or other key topics that are seen by hematologists of key importance • Patient advocates are usually less interested across diseases, so „cherry- picking“ of specific presentation might be best strategy
  • 8. Satellite symposia • Symposia sponsored by a single company on a specific topic/disease • Run on Thursday (today), the day before the scientific meeting • Often in parallel to other meetings, e.g. investigator meetings, or our meeting here • Data presented here is • usually „pharma-compliant“ • usually less complex, more mainstream, more educational, good for the „big picture“ • already published – data presented for the first time at EHA will only be shown in the scientific sessions • This year in parallel to our capacity building meeting
  • 9. Education Sessions • Overview on the „state of play“ and the most important news in your disease area • Usually less complex, good to get the „big picture“ • Usually repeated twice on two different days, to allow to participate in two, and to overcome overlaps • Don‘t miss „your“ education session, they are the basis for the scientific sessions at the congress!
  • 10. Simultaneous/oral sessions • Submitted in March. 195 of them selected in April by EHA Scientific Programme Committee • Those who make it into the „oral sessions“ were rated highest – this is usually the „hot stuff“ • Clinical sessions are very relevant but complex. Forget about biology sessions – hardcore science! • Each session has 75 minutes, with 5 presentations of 15 minutes including Q&A from the audience • To prepare yourself, • Read the abstract of the session (on the web) prior to the session • Make yourself familiar with typical abbreviations • Make yourself heard - queue up to ask a question!
  • 11. Advocacy Sessions • Core target group: Hematologists! • 2 „Patient Advocacy sessions“ defined by patient advocates • Innovative Clinical Trial Designs, Adaptive Pathways (MAPPs) and Patient Involvement in R&D (Saturday, 8:00-9:30, N115) • Pregnancy During and After Treatment: Myths and Reality (Saturday, 11:30-12:45, N115) • 2 “Advocacy Sessions” defined by EHA • EU Funded Projects in Hematology: HARMONY (Saturday, 14:45-15:45, N115) • New drugs in hematology: Fair pricing & access (Saturday, 16:00-17:15) Engage in the EHA Patient Organisations Workgroup to propose topics for 2018!
  • 12. Poster sessions • This is the best place to meet key experts and their key staff members! • „Hot topics“ for us are often on the 500 posters (e.g. QoL, side effects, economics) • Go, ask, understand - there are no silly questions!
  • 13. How do I find interesting posters? • Go to the meeting planner, find your disease area • Ignore „Biology“ (hardcore science) – look for „Clinical“ • „First author“ needs to stand in front of his/her poster for 1,5 hours – perfect opportunity, he/she can‘t escape! • Note down the lowest and highest poster number of interest • Go to Poster area (Hall 7) and find the poster area, they are sorted by poster number. • Note: There are different posters on different days! X X X
  • 14. Why are abstracts so important? • Abstracts are short summaries of scientific news submitted by clinicians who apply to present them at EHA • They are available before the congress starts  read and prepare • After the congres, they can help you getting the facts right in your EHA report
  • 15. How do I access the abstracts? • Go to EHA congress website, „Abstracts Online“ • Select 22nd EHA congress, then e.g. oral or posters • Enter your disease area. Identify those abstracts whose headline is most relevant. Then read the relevant abstracts
  • 16. Patient Advocacy Booth: our meeting point • Joint booth of the EHA Patient Organisations Workgroup (European umbrella organisations) • Use this as your meeting point. You can still go for a coffee at a nearby expo booth • Booth number #560 this year
  • 17. How do I find people from companies in my region or Europe at EHA? • Usually the patient relations people of all companies are at EHA. • They usually check their email and WhatsApp during the congress. • Ask other advocates if they have the contact. • You can also ask staff at the booth of the company.
  • 18. How do I find a clinician who is at EHA? • Check the EHA abstracts in the EHA App or web-based programme. If they are mentioned as first author of an abstract: • In case of a poster abstract, see them at the poster session • In case of an oral presentation, speak to them after their talk • Clinicians usually go to the scientific sessions presented by colleagues. You might find him/her there • Send them an email and ask for a meeting during EHA. For future years: Their schedule is usually very full, so try to ask them for an appointment several weeks in advance.
  • 19. How do I meet and connect with other patient advocates? • Go to the Patient Advocacy Booth • Attend all Patient Advocacy Track sessions • Join our EHA Advocates Facebook Group at http://fb.me/ehaadvocates • Join our Tapas meeting at 21:00 tonight El Patio de la Casa de Córdoba, C/ Víctor de la Serna, 30 Madrid, 28016 • Volunteer to help organise future Patient Advocacy Tracks and Capacity Building sessions
  • 20. Providing feedback to your community: Writing reports • Take notes in scientific sessions • Take photos of slides (secretly). Make sure you cover at least the title slide and the conclusion slide(s), they are crucial. • Look up its abstract later to support writing your report • Take photos of posters. Have a barcode scanner on your phone, often you can scan the poster and get a PDF by email. • Download all interesting abstracts, simplify them and create a summary for your patients. • If you are writing a report on scientific matters, ask a friendly clinician who is attending EHA to ensure accuracy. • Think about who your audience is: Patients? Advocates? Both? Member Organisations? Each of these may need a differently written report
  • 21. The bottom line: How to get the most of EHA • Think about your priorities • There is no better place to meet clinicians and learn about news that are crucial for the life of your patients • Think about the impact for your community, not presence or representation • Build your schedule around the key congress sessions. Refuse to attend other meetings during those sessions! • Don’t go to meetings because you feel obliged, e.g. because they have paid for your flight. You are here for the congress, not to be somewhere else • Learn, network, engage, explore: And don’t forget: Be bold and have fun!
  • 22. EHA / EuroBloodNet Capacity Building: Plenary 1. EuroBloodNet and the ePAG (Pierre Fenaux) 2. Getting the most out of EHA (Jan Geissler) 3. Interpreting and understanding scientific presentations (Tamás Bereczky) Myeloma data at EHA 2017: Anna Sureda Acute Leukemias data at EHA 2017: Gert Ossenkoppele 14:00 MPE Advocate Development Programme MPN data at EHA 2017: Clare Harrison CML data at EHA 2017: Tim Brümmendorf MDS data at EHA 2017: Pierre Fenaux Lymphoma& CLL data at EHA2017: Dr. John Gribben 15:15 15:25 16:55 Track 1, Room N117 Track 2, Room N118 Optional offsite capacity building meetings (optional) 17:30 21:00 Acute Leukemia Advocates Network Joint tapas and drinks of advocates El Patio de la Casa de Córdoba, C/ Víctor de la Serna, 30 Madrid, 28016 20:30 15:55 16:25 14:55 14:30 What‘s next? Crowne Plaza Madrid Airport Hotel